文献速递骨软组织肉瘤与黑色素瘤

骨肉瘤复发二期试验:过往经验系统综述

Phase-II trials in osteosarcoma recurrences: A systematic review of past experience.
PubMed 文献 · Eur J Cancer · 2017-02-20

该系统综述检索2003至2016年注册的骨肉瘤复发二期试验,共纳入99项,其中80项为二期、17项为I/II期、2项为II/III期,多数评价靶向治疗(40项)或单纯化疗(26项)。仅9项为随机设计,主要终点以肿瘤反应为主(71项),但定义与统计假设各异,作者认为目前无法从既往二期疗效试验中得出可靠的历史数据。

要点

  • 99项试验中仅9项为随机设计,65项在多中心开展,17项为国际试验。
  • 71项试验以肿瘤反应为主要终点,但完全缓解、部分缓解、轻微缓解与疾病稳定的定义不一。
  • 在评价反应率的单臂试验中,可获取的12项试验无效假设从5%到25%不等。

核心结论

  • 目前无法从既往疗效二期试验中得出可靠的历史数据,迫切需要在所有年龄段开展采用标准化主要终点的国际随机二期试验。

研究设计与样本

  • 系统综述检索clinicaltrials.gov、clinicaltrialsregister.eu、法国国家癌症研究所网站以及PubMed和美国临床肿瘤学会网站2003年至2016年间注册的临床试验,检索词为(骨肉瘤或骨肉瘤)AND(二期)。
  • 共识别99项试验,其中80项为二期、17项为I/II期、2项为II/III期,主要评价靶向治疗(40项)和单纯化疗(26项)。
  • 28项试验结果已全文发表,6项仅以摘要形式部分发表;24项试验专门针对骨肉瘤,22项设有骨肉瘤分层。
  • 65项试验在多中心开展,包括17项国际试验;仅9项为随机设计。

主要发现

  • 99项试验中28项(28%)涉及复发时观察到的年龄范围。
  • 主要终点为肿瘤反应的有71项(反应率40项或最佳反应31项),采用多种定义(完全缓解+部分缓解±轻微缓解和疾病稳定),主要使用RECIST标准评价(69项)。
  • 主要终点为无进展生存期的有24项,为总生存期的有3项。
  • 在评价反应率的单臂试验中,所检验的无效假设(可获取时12项)从5%到25%不等。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The most appropriate design of Phase-II trials evaluating new therapies in osteosarcoma remains poorly defined. OBJECTIVE: To study consistency in phase-II clinical trials evaluating new therapies for osteosarcoma recurrences with respect to eligibility criteria, response assessment, end-points, statistical design and reported results. METHODS: Systematic review of clinical trials registered on clinicaltrials.gov, clinicaltrialsregister.eu and French National Cancer Institute website or referenced in PubMed and American Society of Clinical Oncology websites, between 2003 and 2016, using the following criteria: (osteosarcoma OR bone sarcoma) AND (Phase-II). RESULTS: Among the 99 trials identified, 80 were Phase-II, 17 I/II and 2 II/III, evaluating mostly targeted therapy (n = 40), and chemotherapy alone (n = 26). Results were fully (n = 28) or partially (abstract, n = 6) published. Twenty-four trials were dedicated to osteosarcoma, 22 had an osteosarcoma stratum. Twenty-eight out of 99 trials refer to the age range observed at recurrence (28%). Overall, 65 trials were run in multicentre settings, including 17 international trials. Only 9 trials were randomised. The primary end-point was tumour response in 71 trials (response rate, n = 40 or best response, n = 31), with various definitions (complete + partial ± minor response and stable disease), mainly evaluated with RECIST criteria (n = 69); it was progression-free survival in 24 trials and OS in 3. In single-arm trials evaluating response rate, the null hypothesis tested (when available, n = 12) varied from 5% to 25%. CONCLUSION: No robust historical data can currently be derived from past efficacy Phase-II trials. There is an urgent need to develop international randomised Phase-II trials across all age ranges with standardised primary end-point.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Omer N, Le Deley MC, Piperno-Neumann S, et al. Phase-II trials in osteosarcoma recurrences: A systematic review of past experience. Eur J Cancer. 2017. PMID: 28219023. doi:10.1016/j.ejca.2017.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。